The Wilms' tumor gene, WT1, is a tumor marker for leukemic blast cells. The WT1 expression levels were examined for 57 patients with myelodysplastic syndromes (MDS) (refractory anemia (RA), 35; RA with excess of blasts (RAEB) 14; RAEB in transformation (RAEB-t), six; and MDS with fibrosis, two) and 12 patients with acute myeloid leukemia (AML) evolved from MDS. These levels significantly increased in proportion to the disease progression of MDS from RA to overt AML via RAEB and RAEB-t in both bone marrow (BM) and peripheral blood (PB). WT1 expression levels in PB significantly correlated with the evolution of RAEB or RAEB-t to overt AML within 6 months. Therefore, WT1 expression levels in PB were superior to those in BM for early prediction of the evolution to AML by means of quantitation of the WT1 expression levels. Furthermore, WT1 expression in PB of patients with overt AML evolved from MDS was significantly decreased by effective chemotherapy or allogeneic stem cell transplantation and became undetectable in long-term survivors. These results clearly showed that WT1 expression levels are a tumor marker for preleukemic or leukemic blast cells of MDS and thus reflect the disease progression of MDS. Therefore, monitoring of WT1 expression levels has made continuous assessment of the disease progression of MDS possible, as well as the prediction of the evolution of RAEB or RAEB-t to overt AML within 6 months. The results also showed that quantitation of WT1 expression levels is useful for diagnosis of minimal residual disease of MDS with high sensitivity, thus making it possible to evaluate the efficacy of treatment for MDS.
Introduction
Myelodysplastic syndromes (MDS) are acquired clonal stem cell disorders characterized by ineffective hematopoiesis involving one or more hematopoietic cell lineages and the resulting peripheral blood cytopenias. 1 MDS are associated with a high risk of evolution to acute myeloid leukemia (AML) and an overall short survival due to the consequences of cytopenias or to transformation to AML. 2 The French-AmericanBritish (FAB) group divided MDS into five subtypes: refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess of blasts (RAEB), RAEB in transformation (RAEB-t), and chronic myelomonocytic leukemia (CMML). 3 The prognosis of MDS was found to correlate to some extent with the subtypes of MDS. However, since there exist great differences in survival between individual patients with the same subtypes of MDS, the FAB classification is not necessarily useful for the diagnosis of the disease progression of MDS or for the prediction of the prognosis for individual patients.
The Wilms' tumor gene WT1 was isolated as a gene respon-sible for Wilms' tumor, a childhood kidney neoplasm and categorized as a tumor suppressor gene. 4, 5 We 6,7 and others [8] [9] [10] [11] have recently shown that the WT1 gene is highly expressed in various types of leukemias (AML, acute lymphoid leukemia (ALL), and chronic myeloid leukemia (CML)) and that the expression of the WT1 gene is thus a tumor marker for leukemic blast cells of almost all leukemias. The WT1 expression levels significantly increased at relapse compared with those at the time of diagnosis. 12 For CML, the WT1 expression levels increased by one log as the clinical stages progressed from the chronic to the accelerated phase and also from the accelerated phase to blastic crisis. 6 Furthermore, WT1 expression levels in bone marrow (BM) or peripheral blood (PB) accurately reflected the extent of minimal residual disease (MRD) of three types of leukemias (AML, ALL and CML). 13 Therefore, the quantitation of the WT1 expression levels by means of reverse-transcriptase polymerase chain reaction (RT-PCR) enabled us to monitor continuously the MRD of individual patients with leukemias, thus making it possible to assess the efficacy of the treatment and to diagnose relapse early at levels of molecular relapse. 6, 13 In the present study, we identified for the first time WT1 expression levels as a tumor marker for preleukemic or leukemic blast cells of MDS. This means that monitoring of WT1 expression levels has made it possible to assess continuously disease progression of MDS, to predict the evolution of RAEB or RAEB-t to overt AML, and to evaluate the efficacy of treatment through the detection of MRD.
Materials and methods

Patients
Fifty-seven patients with newly diagnosed MDS and 12 patients with AML evolved from MDS were analyzed in this study. Basic clinical characteristics of the patients are summarized in Table 1 . The diagnosis of MDS was made according to the French-American-British (FAB) classification. 
Reverse-transcriptase polymerase chain reaction (RT-PCR) for quantitation of WT1 expression levels
Heparinized BM aspirates or PB cells were mixed with isovolumes of phosphate-buffered saline (PBS) and centrifuged on Ficoll-Paque (Pharmacia, Uppsala, Sweden). Mononuclear cells were gathered from mononuclear cell layer and washed twice with PBS to remove platelets. RNA was prepared from the mononuclear cells and converted into cDNA as described previously 6 with a minor modification. In brief, 2 g of total RNA in 12.5 l of diethylpyrocarbonate-treated water was heated at 65°C for 5 min and then mixed with 17.5 l of RT . Therefore, PCR was performed for 36, 33, 30, or 27 cycles according to WT1 expression levels in samples under exponential amplification conditions. Similarly, to determine optimal conditions for PCR to quantitate ␤-actin expression levels, PCR was performed for various cycles using ␤-actin primers (sense primer, 5Ј-GTGGGGCGCCCCAGGCACCCA-3Ј; antisense primer, 5Ј-GTCCTTAATGTCACGCACGATTTC-3Ј) with serial dilutions of the cDNA prepared from total RNA of K562 leukemic cells. Exponential amplification was observed for 19 cycles of PCR in the range from 8 × 10 −1 to 4 × 10 1 ng of RNA, in which ␤-actin expression levels in almost all samples were included, as shown in Figure 1e . To normalize the differences in RNA degradation for individual samples and in RNA loading for RT-PCR, the value of WT1 gene expression divided by that of ␤-actin gene expression was defined as the WT1 expression level in the samples. Calibration curves were shown in every experiment and the WT1 expression levels were quantitated according to the curves. The expression level of the WT1 gene in K562 leukemic cells was defined as 1.0, and the WT1 expression level in the samples were relatively shown compared to that in K562 cells.
Statistical analysis
The statistical significance of differences in WT1 expression levels between subtypes of MDS was assessed by one-way factorial analysis of variance and multiple comparison tests (Scheffe method). The analysis of statistically significant correlation between WT1 expression levels and the evolution to AML within 6 months was performed by unpaired t-test.
Results
Increase in WT1 expression levels proportional with disease progression of MDS toward overt AML
WT1 expression levels in BM or PB were examined for three subtypes of MDS (RA, RAEB, and RAEB-t) ( Figure 2 ). In BM (Figure 2a) , the WT1 expression levels significantly increased in proportion to the disease progression of MDS from RA to overt leukemia (OL) via RAEB and RAEB-t. In about a half of the patients with RA, WT1 expression was within the background levels of normal BM (Ͻ8.0 × 10 −4 ; the WT1 expression level of K562 leukemic cells was defined as 1.0). In all the patients with RAEB or RAEB-t, however, WT1 expression abnormally increased compared to the background levels of normal BM. The disease progression from RA to RAEB or RAEB-t was reflected in a significant increase in WT1 expression levels. However, no significant difference in WT1 expression levels was found between RAEB and RAEB-t. Similarly, in PB (Figure 2b ), WT1 expression levels significantly increased in parallel with the disease progression. In nine (39%) of 24 patients with RA, the WT1 expression was as undetectable as it is in normal PB (Ͻ10 −5 ). The remaining 15 patients with RA showed abnormal levels of WT1 expression widely distributed over a 2-log range. An approximately 2-log difference in WT1 expression levels was found between RA and RAEB, and between RA and RAEB-t. However, no significant difference was found between RAEB and RAEB-t. No correlation between percentages of blasts and WT1 expression levels in BM was found in each subtype of MDS ( Table 2) .
Prediction of disease progression of MDS to overt AML from WT1 expression levels
Whether or not the disease progression of RAEB, RAEB-t, or MDS with fibrosis to overt AML can be predicted from WT1 expression levels was examined (Figure 3 ). In BM (Figure 3a) , no significant difference in WT1 expression levels was found between patients with and those without disease progression to overt AML within 6 months. On the other hand, in PB (Figure 3b) , patients with disease progression to overt AML within 6 months showed WT1 expression levels significantly higher than did patients without such disease progression. These results show that WT1 expression levels in PB are a useful marker for the prediction of disease progression of RAEB, RAEB-t, or MDS with fibrosis to overt AML within 6 months.
Figure 1
Calibration curves for the quantitation of various levels of WT1 expression (a-d) or for the quantitation of expression levels of the ␤-actin gene (e) are shown. For calibration curves, serially diluted cDNA samples from K562 cells were amplified by PCR.
Figure 2
WT1 expression levels in MDS and overt AML evolved from MDS. WT1 expression levels in BM (a) or PB (b) were quantitated by means of RT-PCR. WT1 expression level in K562 leukemic cells was defined as 1.0 as described previously. 6 RA, refractory anemia; RAEB, RA with excess of blasts; RAEB-t, RAEB in transformation; OL, overt leukemia.
Long-term follow-up of WT1 expression levels for patients with MDS
WT1 expression levels of individual patients with MDS were followed up for a long period (Figure 4) . In five untreated patients (RAEB two; RAEB-t, two; MDS with fibrosis one), the disease progressed to overt AML. These disease progressions were associated with either a rapid or a gradual increase in WT1 expression levels. On the other hand, the two patients whose disease did not change from RAEB showed fluctuations but no increase in their WT1 expression levels. However, in one patient with RAEB, the disease progressed to RAEB-t in association with an increase in WT1 expression levels. These results showed that the degree of disease progression toward overt AML can be diagnosed for individual patients by monitoring of WT1 expression levels.
Assessment of the efficacy of treatment for MDS by monitoring of WT1 expression levels
In four patients with overt AML evolved from MDS, who were treated with conventional chemotherapy, or with allogeneic bone marrow or peripheral blood stem cell transplantation, WT1 expression levels were monitored over a long period ( Figure 5 ). These levels decreased in association with a decrease in the number of blast cells in BM after effective treatment. Interestingly, in the two patients treated with allogeneic stem cell transplantation, WT1 expression levels stayed at low levels for 1 year after the treatment and then became undetectable (Figure 5c and d) . These results indicate that monitoring of WT1 expression levels is useful for the detection of minimal residual disease (MRD) of MDS and thus for assessment of the efficacy of individual treatments for MDS. 
Figure 3
A correlation between WT1 expression levels in BM (a) or PB (b) and the evolution of MDS to overt AML within 6 months. ̅, RAEB; ȣ, RAEB-t; , MDS with fibrosis.
Discussion
Our present study clearly demonstrated that WT1 expression levels reflect the degree of disease progression of MDS to overt AML and thus that the monitoring of WT1 expression levels is useful for predicting leukemic transformation of MDS. Several scoring systems [14] [15] [16] [17] [18] for MDS have been developed to evaluate different groups of patients and to predict life expectancy precisely in the individual patient. These scoring systems grade several parameters by allocation of points that have previously been proven to be prognostic relevance by uni-and multivariate analysis. In an International Prognostic Scoring System (IPSS) for MDS, the risk scores for BM blast percentage, cytogenetic abnormalities, and number of cytopenia were evaluated and weighted. By combining the risk scores for these three major variables, patients were stratified into four distinctive risk groups (low, intermediate-1, intermediate-2, and high) regarding both survival and AML evolution. When the correlation between WT1 expression levels and these four risk groups was examined, it was found that the levels in both BM and PB had increased proportionally with the increase in the risk scores (data not shown). This finding confirmed our present results showing that WT1 expression levels reflect the disease progression of MDS. However, since these scoring systems divide the continuous process of disease progression into several discontinuous stages, they are not suitable for assessment of continuous disease progression in individual patients, whose patterns of disease progression vary. On the other hand, since quantitation of WT1 expression levels directly quantifies the abnormal blast cells of MDS, this method enables us for the first time to assess continuously the disease progression of MDS. No correlation was found between percentages of blast cells and WT1 expression levels in BM in each subtype of MDS. This may suggest that WT1 expression levels reflect total amounts of leukemic blast cells and preleukemic cells, but do not reflect only amounts of morphologically typical leukemic blast cells.
The disease progression of RAEB, RAEB-t, or MDS with fibrosis to overt AML within 6 months significantly correlated with WT1 expression levels in PB, but not with those in BM. Therefore, WT1 expression levels in PB are superior to those in BM for early prediction of the evolution to AML. The reason why this correlation was observed in PB but not in BM remains unclear. However, one possibility is that as the evolution to overt AML becomes imminent, preleukemic or leukemic blast cells tend to detach from the bone marrow stromal cells because of the alteration of adhesion molecules associated with the evolution to overt leukemia 19, 20 and to flow into PB, resulting in an increase in WT1 expression levels in PB, but not a significant increase in the levels in BM.
WT1 expression levels were significantly higher for RAEB or RAEB-t than for RA, whereas no significant differences in the WT1 expression levels were seen between RAEB and RAEB-t. These findings suggest the existence of a significant difference in the tumor burden between RA and RAEB, or between RA and RAEB-t, but that the tumor burden in RAEB and RAEB-t is similar. This suggestion is compatible with the clinical finding that no significant difference in prognosis exists between RAEB and RAEB-t. 21 MDS patients whose WT1 expression levels remain stable at lower levels for a long period may die of infection and hemorrhage due to the consequences of pancytopenia instead of dying due to leukemic transformation. Therefore, these patients should be treated conservatively rather than be given cytocidal treatment to prevent infection and homorrhage.
Figure 4
Long-term follow-up of WT1 expression levels in patients with MDS. WT1 expression levels in BM (-) or PB (· · ·) were followedup for MDS patients. ̅, RAEB; ȣ, RAEB-t; , MDS with fibrosis; v, overt AML. Thus, monitoring of WT1 expression levels is also useful for deciding treatment strategies for MDS patients.
For diagnosis of minimal residual disease (MRD) of MDS, a combined method of FACS sorting followed by fluorescence in situ hybridization was used to detect MRD of MDS. 22 However, this method is laborious and very low in sensitivity compared with our method, where one leukemic cell in 100 000 normal peripheral blood mononuclear cells can be detected through quantitation of WT1 expression levels. Therefore, the present study is the first evidence of the establishment of a 398 method which can detect MRD of MDS with high sensitivity. This method has made it possible to diagnose rapidly and sensitively MRD of MDS and thus to evaluate the efficacy of individual treatments for MDS. It has been reported that normal background levels of WT1 expression are Ͻ10 −3 in BM and Ͻ10 −5 in PB. 6 Therefore, a cut-off point for abnormal expression levels of WT1 is 10 −3 for BM and 10 −5 for PB. As for a cut-off point of WT1 expression levels that determines the sensitivity and specificity of WT1 expression as a prognostic factor and a marker for the disease progression of MDS to overt AML, all of eight patients (RAEB or RAEB-t) with more than 10 −3 levels of WT1 expression in PB progressed to overt AML within 2.3 years. Therefore, the levels of WT1 expression that predict with certainty that a patient with RAEB or RAEB-t will progress to overt AML within 2-3 years are 10 −3 in PB. When the WT1 expression levels increased to 10 −3 in PB, bone marrow transplantation should be performed as early as possible.
We have previously reported an aberrant overexpression of wild-type WT1 in leukemia, 6, 7 an inverse correlation between WT1 expression levels and prognosis, 6 increased expression of the WT1 gene at relapse, 12 and growth inhibition of leukemic cells by WT1 antisense oligomers. 23 Furthermore, it has been well known that 32D cl3 myeloid progenitor cells completely differentiate into mature neutrophils in response to granulocyte colony-stimulating factor (G-CSF). However, 32D cl3 myeloid progenitor cells that constitutively express WT1 by the transfection of the WT1 gene stopped differentiating but instead proliferated in response to G-CSF. 24 The blocking of differentiation, but induction of proliferation was associated with constitutive activation of Stat 3␣ and Stat 3␤. On the basis of these findings, we have proposed a hypothesis that the WT1 gene has basically two functional aspects, namely that of a tumor-suppressor gene and that of an oncogene, but that in leukemic cells it performs an oncogenic rather than a tumor-suppressor gene function and plays an essential role in leukemogenesis. Since MDS is supposed to be a pre-leukemic state, the WT1 gene should also play an important role in the development of MDS.
In conclusion, the quantitation of WT1 expression levels enabled us to monitor continuously the disease progression of MDS toward overt AML, to make an early prediction of evolution to AML, and to diagnose MRD of MDS and thus assess the efficacy of treatment for MDS.
